Measure of Outcomes in Patients With Advanced Ovarian Cancer According to Homologous Recombination Status and Matched Therapies in a Real-world Scenario

Launched by CONSORZIO ONCOTECH · Feb 14, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how well different treatments work for women with advanced ovarian cancer, focusing on the tumor's genetic makeup. Researchers want to see how patients with tumors that are "homologous recombination deficient" (HRD) respond to a combination of two drugs, Olaparib and Bevacizumab, after their initial chemotherapy. They will compare this group (Cohort A) to women whose tumors are "homologous recombination proficient" (HRP) and are being treated with standard therapies chosen by their doctors (Cohort B). The goal is to understand the effectiveness and safety of these treatment options in real-world settings.

To take part in the study, women must be at least 18 years old and have a diagnosis of high-grade ovarian cancer that has been tested for its HR status using approved methods. They should not have certain genetic mutations related to ovarian cancer or have died before joining the study. Participants can expect to be part of a large group of women from different centers and will have their treatment outcomes monitored over time. This study is currently recruiting participants until January 2026, and those interested can learn more from their healthcare provider.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Female, age ≥ 18 years at the time of diagnosis
• * Patients diagnosed with high-grade serous or endometroid ovarian, fallopian tube, or primary peritoneal cancer undergone to Homologous Recombination test with the MyChoice HRD assay, FoundationOne DX assay or another validated HRD test, between January 2021 and January 2026:
• • Patients with HRD score \> 42 or Loss of Heterozygosity (LOH) score high or defined as HR deficient with other tests and treated with Bevacizumab and Olaparib after first line platinumbased chemotherapy will be retrospectively or prospectively enrolled in Cohort A
• • Patients with HRD score \< 42 or Loss of Heterozygosity (LOH) score low or defined as HR proficient with other tests and treated with first line platinum-based chemotherapy with or without bevacizumab or others targeted agents will be retrospectively or prospectively enrolled in Cohort B
• • Patients must be able to understand the study procedures and agree to participate in the study by providing written informed consent.
• Exclusion Criteria:
• • Patients who have not performed a validated Homologous Recombination test on tumor sample.
• • Patients with germline or somatic BRCA 1 or 2 mutations
• • Patients death at the time of inclusion in the current study